ESP Block Vs. QIPB for Lumbar Stabilization Surgery

NCT07789509 | Not Yet Recruiting

• 1 other identifier: QİPBvsESP
• Study Type: interventional
• Target: 60
• Locations: 0 countries
• Sites: N/A

Brief Summary

This randomized clinical trial aims to evaluate and compare the analgesic efficacy and functional outcomes of the quadro-iliac plane block (QIPB) and the erector spinae plane block (ESPB) in patients undergoing lumbar stabilization surgery. The primary outcome is the Numeric Rating Scale (NRS) within the first 48 hours after surgery. Secondary outcomes include postoperative total opioid consumption, incidence of quadriceps motor block, time to first ambulation, block performance time, falls, length of hospital stay, block-related complications (hematoma, local anesthetic systemic complications, vascular puncture, and infection), patient satisfaction assessed using a Likert scale, and incidence of postoperative nausea and vomiting.

Conditions

Quadro-Iliac Plane Block; Erector Spina Plan Block; Lumbar Stabilization Surgery; Pain Management

Keywords

QIPB; ESP; Lumbar; Analgesia

Outcome Measures

Primary Outcomes (1)

• Postoperative pain scores

  Postoperative pain intensity will be assessed using an 11-point Numeric Rating Scale (NRS), where 0 indicates no pain and 10 indicates the worst imaginable pain. Pain scores at rest will be recorded in the post-anesthesia care unit and at postoperative 6, 24, 36, and 48 hours. Pain scores during movement will be assessed during passive flexion of the operated hip at postoperative 6, 24, 36, and 48 hours.

  6,24,36,48 hours

Secondary Outcomes (9)

• Postoperative opioid consumption

  postoperative 24 and 48 hours

• Incidence of quadriceps motor block

  Postoperative 3, 6, and 24 hours

• Time to first ambulation

  Postoperative day 1

• Patient satisfaction

  Postoperative 48 hours

• Postoperative nausea and vomiting (PONV)

  Postoperative 48 hours

Study Arms (2)

quadro-iliac plane block (QIPB)

ACTIVE COMPARATOR

Participants allocated to the QIPB group will receive an ultrasound-guided quadro-iliac plane block after the induction of general anesthesia. Following standard aseptic preparation, 30 mL of 0.25% bupivacaine will be administered into the target fascial plane under ultrasound guidance after confirming the absence of blood on aspiration.

Procedure: Quadro iliac Plane Block

Erector Spina Plane Block

ACTIVE COMPARATOR

Participants in the ESPB group will undergo an ultrasound-guided erector spinae plane block after the induction of general anesthesia. A total of 20 mL of 0.25% bupivacaine will be administered into the target fascial plane under ultrasound guidance after confirming the absence of blood on aspiration.

Procedure: Quadro iliac Plane Block

Interventions

Quadro iliac Plane Block PROCEDURE

Participants allocated to the QIPB group will receive an ultrasound-guided quadro-iliac plane block after the induction of general anesthesia. Following standard aseptic preparation, 30 mL of 0.25% bupivacaine will be administered into the target fascial plane under ultrasound guidance after confirming the absence of blood on aspiration.

Erector Spina Plane Block; quadro-iliac plane block (QIPB)

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age between 18 and 80 years
• American Society of Anesthesiologists physical status I-III
• Scheduled for elective primary lumbar stabilization surgery
• Surgery planned under general anesthesia
• Ability to understand and use the Numeric Rating Scale
• Written informed consent provided

You may not qualify if:

• Refusal to participate
• Revision lumbar stabilization surgery
• Contraindication to regional anesthesia
• Contraindication to peripheral nerve/plane block
• Known allergy to local anesthetics or study drugs
• Coagulopathy or anticoagulant use incompatible with neuraxial/regional -anesthesia
• Infection at the block injection site
• Pre-existing neurological deficit involving the lower extremities (unrelated to t-he current spinal pathology)
• Peripheral neuropathy
• Chronic opioid use
• Cognitive impairment or inability to communicate reliably
• Severe hepatic or renal failure
• Body mass index \> 35 kg/m2
• Pregnancy

Sponsors & Collaborators

• Antalya City Hospital: lead

MeSH Terms

Conditions

Agnosia

Condition Hierarchy (Ancestors)

Perceptual Disorders; Neurobehavioral Manifestations; Neurologic Manifestations; Nervous System Diseases; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Central Study Contacts

Damla Kaytancı Özçelik, MD

CONTACT

+905075124445; damla.kaytanci@saglik.gov.tr

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: PARTICIPANT
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 1, 2026
• First Posted: August 27, 2026
• Study Start (Estimated): November 15, 2026
• Primary Completion (Estimated): August 15, 2027
• Study Completion (Estimated): September 15, 2027
• Last Updated: August 27, 2026

Record last verified: 2026-07

Data Sharing

• IPD Sharing: Will not share